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The combination of mexiletine and a class Ie antiarrhythmic 
agent (encainide, propafenone or f1ecainide) was evaluated by 
electrophysiologic testing in 14 patients with a history of sustained 
ventricular tachycardia whose tachycardia remained inducible 
during therapy with the class Ie drug alone. During the control 
drug-free state, all patients had inducible ventricular tachycardia, 
with a mean cycle length of 260 ms (range 190 to 400). During 
monotherapy with the Ie agent the tachycardia remained induc-
ible in each patient, but there was a significant increase in the 
cycle length to 340 ms (240 to 500) (p < 0.001). The effective 
refractory period of the ventricle was not altered. 
Treatment with mexiletine (oral in 13 and intravenous in 1) 
was begun and electrophysiologic testing was repeated. Ventricu-
lar tachycardia in one patient was rendered noninducible and one 
patient had arrhythmia aggravation. The tachycardia in the 
Antiarrhythmic agents remain an established and frequently 
used method for treating serious ventricular arrhythmias. 
However, in many patients the arrhythmia will not be 
successfully controlled with a single agent. When evaluated 
by noninvasive methods, only 40% to 60% of patients 
respond to monotherapy, whereas with electrophysiologic 
techniques the arrhythmia becomes noninducible in only 
10% to 30% of patients (l,2). In addition, many patients will 
experience intolerable or disturbing side effects at doses 
necessary to achieve arrhythmia suppression and discontin-
uation of the drug may be required. 
In recent years a commonly used approach to manage-
ment is the combined use of antiarrhythmic agents; this 
approach is particularly important when monotherapy is 
only partially effective (3). Several studies (4-7) have re-
ported that combination drug therapy may enhance antiar-
rhythmic efficacy when compared with the effect of each 
agent administered singly. In addition, the use of drug 
combinations may result in the need for smaller doses of 
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remaining 12 patients remained inducible but its average cycle 
length increased further to 392 ms (340 to 460) (p = NS). 
Nine patients had rate slowing and the average cycle length of 
the ventricular tachycardia in this group was significantly in-
creased (302 to 388 ms, p < 0.05). The average effective refractory 
period was significantly increased during combination therapy 
(267 ms) compared with no drug therapy (235 ms) and therapy 
with the class Ie drug alone (247 ms) (p < 0.05). After a mean 
follow-up interval of 22 months, seven patients continue on the 
combined treatment and have no ventricular tachycardia. 
It is concluded that although the combination of mexiletine 
with a class Ie antiarrhythmic agent does not often render the 
patient's ventricular tachycardia noninducible, it causes in most 
patients further slowing of the rate of induced tachycardia, which 
may be of clinical importance. 
(J Am Coil CardioI1991;17:1396-402) 
each drug to achieve arrhythmia suppression, therefore 
minimizing or preventing side effects. 
Most often reported (4,5) is the combined use of a 
membrane-active drug and a beta-adrenergic blocking agent. 
However. combinations of two membrane-active (class I) 
agents have also been used successfully to treat ventricular 
arrhythmias that are refractory to monotherapy (6,7). These 
drugs depress the rate of depolarization of the myocardial 
cell membrane by interacting with and blocking the sodium 
channel (8). The affinity of a particular agent for the sodium 
channel is dependent on the state of the channel-that is, at 
rest, activated or inactivated (9). Theoretically, combining 
different class 1 agents will be beneficial for arrhythmia 
suppression as a result of blockade of the sodium channel 
during different phases of the action potential, producing 
additive antiarrhythmic effects. 
Mexiletine, a lidocaine congener, is a class IB agent that 
is effective for the treatment of sustained ventricular ar-
rhythmias. However. as monotherapy, the arrhythmia be-
comes noninducible in only 10% to 15% of patients when 
electrophysiologic techniques are used (10). The class IC 
agents, including encainide. flecainide and propafenone, are 
also effective for sustained ventricular arrhythmia, and in 
15% to 30% of patients the arrhythmia is rendered noninduc-
ible (11-13). Because the class IB and IC agents appear to 
have different electrophysiologic actions on the sodium 
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Table 1. Patient Characteristics 
No. of patients 
Male/female ratio 
Age (yr) 




Prior antiarrhythmic therapy 
Congestive heart failure 
LVEF (%) (range) 
14 
11/3 







34 (15 to 50) 
LVEF = left ventricular ejection fraction: NSVT = non sustained ventric-
ular tachycardia: VT = ventricular tachycardia. 
channel and eiectrophysiologic properties of the myocar-
dium, the use of mexiletine in combination with a class IC 
drug may result in an additive or even synergistic effect on 
arrhythmia suppression. 
The purpose of this study was to determine the effect of 
mexiletine in combination with a class IC drug on the 
induction of a sustained ventricular tachyarrhythmia. 
Methods 
Study patients (Table 1). The study group included 14 
patients, 11 men and 3 women, with an average age of 63 
years (range 37 to 77). Ischemic heart disease was present in 
II patients, whereas 3 had idiopathic dilated cardiomyopa-
thy. The presenting clinical arrhythmia was sustained ven-
tricular tachycardia associated with hypotension or syncope 
in 13 patients, whereas I patient had documented frequent 
and long runs of nonsustained ventricular tachycardia asso-
ciated with presyncope. Eight patients had not received 
treatment with antiarrhythmic medication before entry into 
the study. 
A history of overt congestive heart failure was present in 
7 of the 14 patients, but all patients had been in clinically 
stable condition for at least I month before entry into this 
study. The average left ventricular ejection fraction for the 
group. as assessed by radionuclide imaging. echocardiog-
raphy or cardiac catheterization, was 34% (range IS% to 
SO%). 
Baseline monitoring. All patients were admitted to a 
telemetry unit for continuous electrocardiographic (ECG) 
monitoring while in the hospital. Previously administered 
antiarrhythmic agents were discontinued for at least 48 h or 
S half-lives before all baseline studies. Digoxin, diuretic 
drugs, beta-adrenergic blocking agents, calcium channel 
blocking agents and nitrates were continued if clinically 
indicated, but the doses of these agents were not altered 
during the study. After an appropriate washout period. each 
patient underwent 48 h of continuous ambulatory ECG 
monitoring and a symptom-limited exercise test on a motor-
ized treadmill. At the completion of these noninvasive 
studies, a baseline electrophysiologic test was performed 
with patients in the drug-free state. 
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Electrophysiologic testing. The protocol for electrophysi-
ologic testing has been previously reported (14). The right 
ventricular apex was paced at two different cycle lengths 
(600 and 400 ms) and up to three extrastimuli were added 
sequentially until an end point was obtained. If an end point 
was not achieved with apical pacing, the entire stimulation 
protocol was repeated from the right ventricular outflow 
tract. The end point for the study was the induction of a 
sustained monomorphic ventricular tachycardia, defined as a 
repetitive arrhythmia lasting for> 30 s or requiring termina-
tion in <30 s because of hemodynamic instability. In each 
case the tachycardia was identical to the clinical arrhythmia. 
Antiarrhythmic therapy. At the conclusion of the base-
line studies, therapy with a class IC antiarrhythmic agent 
was initiated. The dosing schedule was as follows: encain-
ide, 2S mg three times/day for 3 to 4 days, 3S mg three 
times/day for 3 to 4 days, SO mg three times/day for 3 to 4 
days; flecainide. 100 mg two times/day for 3 to 4 days. 
ISO mg two times/day for 3 to 4 days, 200 mg two times/day 
for 3 to 4 days; propafenone, ISO mg three times/day for 3 to 
4 days. 300 mg three times/day for 3 to 4 days. 
The drug dose was titrated on the basis of occurrence of 
side -€ffects. including ECG interval changes and. when 
present. the suppression of spontaneously occurring ventric-
ular arrhythmia as evaluated by telemetric monitoring. Each 
day during treatment patients were seen and examined by 
one of the investigators and ECG intervals were measured. 
At the completion of the dosing period, 24 h ambulatory 
ECG monitoring, a symptom-limited exercise test and an 
electrophysiologic study were repeated. The criterion for 
drug efficacy was non inducibility , defined as the induction of 
< IS repetitive ventricular beats occurring after the last 
premature stimulus added. 
While receiving the class IC drug, each patient in this 
study continued to exhibit inducibility of a sustained mono-
morphic ventricular tachycardia that was identical in config-
uration to the clinical arrhythmia and that provoked during 
the baseline study. After electrophysiologic testing during 
treatment with the class IC drug was performed, therapy 
with oral mexiletine at a dose of ISO mg. three times/day was 
initiated. After 3 days of combination therapy, ambulatory 
ECG monitoring. exercise testing and an electrophysiologic 
test were repeated. All subjects gave informed consent for 
electrophysiologic studies, exercise tests and intravenous 
drug administration. 
Statistics. Statistical comparisons were performed using 
the Student's two-tailed paired t test. Significance was 
defined as p :::::; O.OS. 
Results 
Baseline electrophysiologic study. Each of the 14 patients 
had an arrhythmia induced from the right ventricular apex 
during the baseline study. A sustained monomorphic ven-
tricular tachycardia was provoked in 13 patients, whereas 
the 1 patient with a history of symptomatic non sustained 
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Table 2. Effect of Drug Therapy on Ventricular Tachycardia 
Cycle Length and Refractory Period in 14 Patients 
VT Cycle VT Rate ERP 
Length (ms) (beats/min) (ms) 
Control 260 231 235 
Class IC monotherapy 340* 176* 247 
Class IC and IB combined 
Total group (n '" 14) 362* 166* 267t 
9 Patients with rate 392* 153* 267t 
slowing 
*p < 0.001 compared with control; tp < 0.05 compared with baseline and 
class IC monotherapy: *p < 0.05 compared with class IC monotherapy. 
ERP '" effective refractory period; VT '" ventricular tachycardia. 
ventricular tachycardia had monomorphic nonsustained ven-
tricular tachycardia reproducibly induced. In each case the 
induced tachycardia was identical in configuration and rate 
to the clinical arrhythmia. Arrhythmia was provoked in 1 
patient with one extrastimulus, in 10 patients with two 
extrastimuli and in 3 patients with three extrastimuli. The 
average cycle length of the induced tachycardia was 260 ms 
(rate 231 beats/min) and ranged from 190 to 400 ms (rate 150 
to 316 beats/min). The effective refractory period, deter-
mined at a pacing cycle length of 600 ms, was 235 ms (range 
210 to 260). Sustained ventricular tachycardia was termi-
nated by overdrive pacing in six patients, whereas seven 
required emergency direct current cardioversion because of 
hemodynamic collapse. The one patient with monomorphic 
nonsustained ventricular tachycardia had spontaneous ter-
mination of the tachycardia after 12 s. This arrhythmia was 
reproducibly induced. 
Electrophysiologic results of class IC drug therapy (Table 
2). Encainide was administered to six patients, propafenone 
was the class IC drug used in five, whereas three patients 
received fiecainide. The average daily dose was 100 mg for 
encainide, 630 mg for propafenone and 233 mg for fiecainide. 
Although the arrhythmia remained inducible during therapy 
with the class IC drug in each patient, the cycle length of the 
induced ventricular tachycardia was significantly prolonged 
by the drug as compared with baseline, from 260 to 340 ms 
(range 240 to 500) (p < 0.001). Accordingly, the rate of 
tachycardia was also significantly slowed from 230 to 176 
beats/min (p < 0.001). However, six patients required emer-
gency cardioversion because of hemodynamic collapse. In 
10 patients the number of extra stimuli to induce ventricular 
tachycardia during therapy was the same as that in the 
control period. In three patients, two receiving propafenone 
and one encainide, three extrastimuli were required to 
induce the tachycardia during drug treatment as compared 
with two extrastimuii at baseline. The arrhythmia was easier 
to induce during propafenone therapy in one patient, requir-
ing two extrastimuli as compared with three during the 
control test. For the entire group, the average effective 
refractory period measured at a cycle length of 600 ms was 
247 ms (range 210 to 280). This value was not significantly 
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different from that measured during baseline (p > 0.05) 
(Table 2). 
Electrophysiologic results of combination therapy (Table 
2). After the electrophysiologic test to evaluate the effect of 
monotherapy with the class IC drug, 13 patients were started 
on oral mexiletine therapy. The mean total daily dose of drug 
administered was 585 mg (range 450 to 750) in three divided 
doses. One patient received 300 mg of mexiletine by intra-
venous infusion after the electrophysiologic study and test-
ing was repeated immediately after the infusion. The average 
daily dose of the class IC drug administered during mexile-
tine therapy was unchanged. 
In only one patient was the tachycardia rendered nonin-
ducible on a repeat electrophysiologic test during therapy 
with the combination of mexiletine and a class IC drug. The 
patient who received intravenous mexiletine experienced 
aggravation of arrhythmia, with induced ventricular fibrilla-
tion requiring defibrillation. 
In the remaining 12 patients, the arrhythmia remained 
inducible; in 11 of the 12 patients monomorphic ventricular 
tachycardia occurred that was identical in configuration to 
the tachycardia observed during the control period and 
during treatment with the class IC drug alone. In the one 
patient with nonsustained ventricular tachycardia, the ar-
rhythmia also remained inducible and the length, rate and 
configuration were identical to the control arrhythmia and to 
that induced during treatment with the class IC drug alone. 
For the entire group of 12 patients, there was a trend toward 
a longer cycle length of the induced tachycardia with the 
addition of mexiletine (362 ms, range 340 to 460) as com-
pared with that with the class IC agent alone (340 ms), but 
this difference did not reach statistical significance (Table 2). 
However, three patients had no change in cycle length, 
whereas in nine there was an increase in the cycle length of 
the tachycardia. In these nine patients, the prolongation with 
the addition of mexiletine from 334 to 392 ms was statisti-
cally significant (p < 0.05). In each of the 11 patients with 
sustained tachycardia, overdrive pacing was effective and 
cardioversion was not required. 
Of the 12 patients in whom monomorphic ventricular 
tachycardia was still inducible during combination therapy, 9 
required the same number of extrastimuli for induction. In 
one patient, who was receiving flecainide and mexiletine, the 
tachycardia was more difficult to induce than during therapy 
with flecainide alone or at baseline. In two patients, one 
receiving mexiletine with propafenone and one mexiletine 
with flecainide, the arrhythmia became easier to induce. 
For the whole group, as well as the nine patients with rate 
slowing, the mean effective refractory period of the ventric-
ular myocardium at a pacing cycle length of 600 ms was 
significantly prolonged during combination therapy (267 ms) 
as compared with that at baseline (235 ms) or during mono-
therapy with the class IC agent (247 ms) (p < 0.05 for both 
comparisons) (Table 2). 
Side effects. Combination therapy did not result in any 
additional ECG changes; specifically, there was no further 
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prolongation of the QRS or QT interval in comparison with 
values during monotherapy. However, combination drug 
therapy resulted in sinus and atrioventricular node dysfunc-
tion in one patient who developed an escape junctional 
rhythm, blocked atrial premature beats and sinus pauses. 
This resolved when the dose of the class IC drug was 
decreased. One patient receiving propafenone and mexile-
tine developed mild congestive heart failure, which resolved 
with reduction of propafenone dose. No patient developed 
any other side effects during therapy with the class IC drug 
alone and there were no side effects with combination 
therapy. As indicated, one patient experienced arrhythmia 
aggravation, which was the induction of ventricular fibrilla-
tion during repeat study. 
Long-term follow-up. All nine patients with significant 
rate slowing were discharged on the effective drug combina-
tion. The average follow-up interval has been 22 months 
(range 2 days to 36 months). Two patients have died, after 2 
days and 18 months, respectively, and the remaining seven 
patients have continued on their drug program without 
arrhythmia recurrence or side effects. 
Discussion 
Cellular electrophysiologic properties of class I antiar-
rhythmic drugs. The class I antiarrhythmic agents bind to 
receptors in the sodium channel and are potent inhibitors of 
the fast inward sodium current (8). They have been divided 
into three subgroups based on the magnitude of their effects 
on the cardiac action potential and the time for repolariza-
tion (15). However, recent advances in cellular electrophys-
iology have made it possible to categorize the class I agents 
according to their specific interaction with the sodium chan-
nel. The modulated-receptor hypothesis developed by Hon-
deghem and Katzung (9,16) postulates that the affinity of an 
antiarrhythmic drug for the sodium channel is dependent on 
the state of the channel-that is, rested, activated or inacti-
vated. Each class I agent has preferential binding to the 
sodium channel when it is in either the activated or the 
inactivated state. These agents are therefore referred to as 
use dependent, their electrophysiologic properties being 
directly related to heart rate (17,18). As the frequency of 
myocardial stimulation increases, there is increased binding 
of the antiarrhythmic agent to available sodium channels 
because more of the channels are in the activated or the 
inactivated state. As a result, the decrease in upstroke 
velocity of the action potential and the slowing of impulse 
conduction are more profound. 
Each class I agent has binding characteristics that are 
unique to that drug. Thus, quinidine, disopyramide and 
procainamide bind preferentially to the sodium channel 
when it is in the activated state, whereas the class IB drugs, 
lidocaine, mexiletine and tocainide, bind to the inactivated 
sodium receptor (9,19). The corresponding data for the class 
IC drugs are not yet established, but these agents appear to 
have actions similar to those of quinidine, with preferential 
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binding to the activated sodium channel. These agents also 
differ with respect to their association and recovery times 
from the sodium channel. For class IC drugs, binding to the 
sodium channel develops slowly and is tight, whereas for 
class IB agents this interaction develops quickly and is loose 
(9.18,19). The binding kinetics of class IA agents are inter-
mediate. During recovery, class IB drugs rapidly and com-
pletely dissociate from the sodium channel, whereas disso-
ciation is slow with class IA agents. Dissociation of class IC 
drugs is also slow and incomplete. These differences in class 
I agents with respect to sodium channel affinity and binding 
kinetics perhaps provide a rationale for their use in combi-
nation, providing additive or even synergistic activity for the 
alteration of e\ectrophysiologic properties of the myocar-
dium and suppression of arrhythmia. 
Many available studies have reported the effects of a 
combination of class IA and IB agents, especially quinidine 
with mexiletine (6,20,21). In vitro animal studies (22) have 
shown that these two agents in combination produce elec-
trophysiologic changes that are more pronounced than those 
obtained with either drug alone. It has been observed (22) 
that quinidine and mexiletine in combination act synergisti-
cally to markedly depress the upstroke velocity of the action 
potential in canine Purkinje fibers. Additionally, the prolon-
gation of the action potential duration or repolarization time 
due to quinidine was reversed by the addition of mexiletine. 
Mexiletine and quinidine in combination resulted in greater 
prolongation of the effective refractory period than that 
observed with either drug alone. 
Efficacy of combination class IA and class IB antiarrhyth-
mic drug therapy. Several clinical trials have shown im-
proved antiarrhythmic efficacy of class IA and IB combina-
tion therapy over that of single agent therapy. Duff et al. (6) 
reported that in 17 patients with frequent ventricular ectopic 
activity and nonsustained ventricular tachycardia as as-
sessed by ambulatory ECG monitoring, only 59% of the 
ventricular premature beats were suppressed with quinidine 
therapy alone, and 65% of the patients had elimination of 
runs of nonsustained ventricular tachycardia. With mexile-
tine as monotherapy, 62% of the ventricular premature beats 
were suppressed, and only 41 % of the patients had complete 
abolition of nonsustained ventricular tachycardia. When 
these two agents were administered together at doses lower 
than those administered during monotherapy, 86% of the 
premature beats were suppressed and nonsustained ventric-
ular tachycardia continued to be present in only 1 of 17 
patients. In addition, the incidence of side effects with 
combination therapy decreased to 18% as compared with 
82% when mexiletine or quinidine was administered alone, a 
result of dose reductions of the antiarrhythmic medications 
when used in combination. Similar results were reported by 
Kim et al. (23), who administered disopyramide in combina-
tion with mexiletine. Of 21 patients with a high density of 
spontaneous arrhythmia documented with ambulatory ECG 
monitoring, 5 (24%) responded to therapy with disopyramide 
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alone and 3 (14%) to mexiletine alone, whereas 13 (62%) had 
arrhythmia suppression with the combination. 
When invasive techniques were used to evaluate drug 
efficacy, a similar improvement in arrhythmia control was 
reported with combination drug therapy. DiMarco et al. (21) 
reported that among 89 patients with life-threatening ventric-
ular arrhythmias, the arrhythmia was noninducible in 34% 
receiving quinidine therapy. The arrhythmia became nonin-
ducible in an additional seven patients when mexiletine was 
used in combination with quinidine, thus increasing the 
response rate by 25%. Greenspan et al. (20) studied the 
effects of quinidine or procainamide in combination with 
mexiletine in 23 patients with sustained ventricular tachy-
cardia. No patient had responded to these agents when they 
were used alone. In eight patients (35%) the arrhythmia was 
noninducible during electrophysiologic testing when combi-
nation therapy was administered. In the remaining 15 pa-
tients, the cycle length of the induced tachycardia was 
prolonged as compared with that at baseline and during 
therapy with the class IA agent alone. The plasma levels of 
each drug when used alone were not significantly different 
from the levels achieved during combination therapy, sug-
gesting that the improved antiarrhythmic efficacy was sec-
ondary to synergistic electrophysiologic effects of class IA 
agents with mexiletine. 
Efficacy of combination class IA and class Ie antiarrhyth-
mic drug therapy. Similar but limited data exist regarding 
combination of class IC and class IA agents. Klein and 
Marcus (7) reported on 30 patients treated with quinidine or 
procainamide as monotherapy, a combination of the class IA 
drug with low dose propafenone (150 mg three times/day), 
low dose propafenone as monotherapy and higher dose 
propafenone (300 mg three times/day) as monotherapy. The 
combination of the class IA drug with propafenone was more 
effective than was monotherapy with either the class IA drug 
or low dose propafenone, but was comparable with the 
results achieved with higher dose propafenone as monother-
apy. 
Efficacy of combination class IB and class Ie antiarrhyth-
mic drug therapy. Few data are available concerning the 
efficacy of class IC agents in combination with class IB 
drugs. Ross et al. (24) reported the electrophysiologic effects 
and efficacy of encainide administered along with lidocaine 
in 20 patients with sustained monomorphic ventricular 
tachycardia refractory to encainide treatment alone. With 
the addition of lidocaine, the tachycardia in all 20 patients 
remained inducible, but the effective refractory period and 
the cycle length of the induced tachycardia were significantly 
prolonged as compared with those measured during encain-
ide monotherapy. No serious side effects were reported with 
this drug combination. Wharton et al. (25) studied the 
efficacy of a class IB and class IC combination in 18 patients 
with sustained ventricular tachycardia inducible during ther-
apy with a class IC agent alone. Four patients required 
discontinuation of combination therapy because of intolera-
ble noncardiac side effects (three patients) or aggravation of 
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arrhythmia (one patient). In only one patient (8%) was the 
arrhythmia noninducible during treatment with the combina-
tion of a class IC and a class IB drug. In the remaining 13 
patients the mean cycle length of the induced ventricular 
tachycardia during combination therapy was significantly 
longer than that measured during baseline studies. However, 
in the study of Wharton et al. (25) there was no difference 
between the tachycardia cycle length observed during mono-
therapy with the class IC agent and that observed during 
combined class IC and class IB therapy. 
Efficacy of combination class Ie antiarrhythmic drug and 
mexiletine therapy. In our study only one patient had ar-
rhythmia that was noninducible during combination therapy 
with a class IC drug and mexiletine. However, in contrast to 
the Wharton study (25), we did observe an increase in the 
ventricular tachycardia cycle length that was significant 
among the nine patients who had further slowing of the 
tachycardia rate during therapy with the combination. Ad-
ditionally, we observed an increase in the effective refrac-
tory period, another marker of antiarrhythmic effect, during 
combination therapy compared with that measured at base-
line or during monotherapy with a class IC agent. 
The significant increase in cycle length that occurred with 
the addition of mexiletine to the class IC agent is unlikely to 
be an effect of mexiletine itself. Although we did not 
evaluate monotherapy with mexiletine because its efficacy 
rate is low in this population, multiple studies have reported 
that mexiletine only insignificantly prolongs the cycle length 
of the induced ventricular tachycardia over that of drug-free 
baseline state (10). With combination therapy the further 
increase in cycle length is unlikely to be an effect of 
mexiletine itself, but suggests additive blockade of the 
sodium channel. 
Clinical significance of ventricular tachycardia rate slow-
ing. The significance of rate slowing in patients whose 
ventricular tachycardia remains inducible while receiving IC 
monotherapy or combination therapy is not known. How-
ever, this may represent a beneficial effect of the drug as has 
been observed with amiodarone (26). Although few patients 
have arrhythmia that becomes noninducible during amio-
darone therapy, the drug often results in a significant slowing 
of the tachycardia rate and prolongation of the effective 
refractory period and it has been reported (26) that these 
changes predict improved survival because the rate of sud-
den death is equivalent to that observed in patients with 
tachycardia that becomes noninducible. Although these pa-
tients do have recurrences of their clinical arrhythmia, the 
tachycardia rate is slower and thus the arrhythmia is better 
tolerated and not life threatening. These findings were in-
deed obtained in our patients. Nine patients whose tachy-
cardia remained inducible on combination therapy had a 
significant slowing of the induced arrhythmia and no hemo-
dynamic collapse, although the number of extrastimuli re-
quired to provoke the arrhythmia during combination ther-
apy was not significantly different from that required at 
baseline study or with the class IC agent alone. The nine 
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patients with rate slowing were discharged on treatment with 
the class IC drug plus mexiletine, and seven remain free of 
tachycardia recurrence after an average of 22 months. There 
were two deaths, but only one occurred early after discharge 
(2 days) and the other occurred after 18 months of therapy. 
This finding suggests that significant rate slowing may be a 
reliable end point of drug therapy. However, the number of 
patients included in this trial is small and further studies are 
necessary to determine the prognostic significance of rate 
slowing in patients treated with combination therapy. 
Limitations of the study. An important limitation of this 
study is the lack of blood drug level determinations. It is 
possible that the observed effects on the ventricular tachy-
cardia rate were due to an increase in the blood level of the 
class IC drug caused by mexiletine. However, this is very 
unlikely. No further ECG changes were noted when mexi-
!etine was added, nor were there any side effects or signs of 
toxicity. In clinical trials, blood levels of class IC drugs are 
very variable and have not correlated with drug efficacy nor 
have changes in blood levels been associated with the 
observed effects of combination therapy (6,7,20). There is no 
known interaction between class IC drugs and mexiletine, 
although this requires further study. 
The significant increase in the effective refractory period 
with combination therapy observed in this study is an 
electrophysiologic effect not characteristic of either mexile-
tine or the class IC agents. Class IC drugs will prolong the 
refractory period to a minimal extent (12,13) in a non-dose 
related fashion and this was observed in our study as the 
mean effective refractory period during this therapy was 
slightly longer than that at baseline, although this difference 
was not significant. Class IB agents do not affect or may 
actually shorten the refractory period, an effect that is also 
unrelated to blood levels 00,15). Therefore, the significant 
prolongation of the effective refractory period during com-
bination therapy probably is secondary to synergistic actions 
of these agents on the sodium channel rather than related to 
blood drug level changes. As previously discussed, a similar 
change in the refractory period was observed in the studies 
of Duff et al. (22) when quinidine and mexiletine were 
administered together and by Ross et al. (24), who used 
encainide and lidocaine. Improved antiarrhythmic activity is 
associated with agents that increase the effective refractory 
period relative to action potential duration. Theoretically, if 
the action potential duration remains unchanged or is short-
ened, these agents in combination should improve antiar-
rhythmic efficacy by increasing the effective refractory pe-
riod to action potential duration ratio (21). Additional studies 
are necessary to determine whether these electrophysiologic 
changes are clinically important. 
Conclusions. Combinations of antiarrhythmic agents are 
frequently used in clinical practice when therapy with a 
single agent fails to suppress an arrhythmia or is associated 
with dose-related side effects. Few data are available con-
cerning the efficacy of IB and IC agents administered in 
combination. However, differences in their binding affinity 
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for the sodium channel support such use. In the present 
study the combination did not improve antiarrhythmic ef-
ficacy as judged by noninducibility, but there were signifi-
cant increases in the cycle length of the induced ventricular 
tachycardia and of the effective refractory period. Although 
the clinical meaning of these findings is not certain, these 
electrophysiologic changes may be important relative to 
arrhythmia recurrence and rate of sudden death. Further in 
vitro clinical electrophysiologic studies and long-term fol-
low-up are necessary to determine whether combinations of 
class IC and class IB agents are a safe and effective means of 
controlling serious ventricular arrhythmias. 
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